EGFR and non-small cell lung carcinoma: For patients receiving carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations, the respective 1- and 2-year survival NEJ002 (CBDCA/PTX) was 86.8% and 53.7% (Inoue et al., 2013).